Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events

• Main Authors: Theodore J. Wigle (Author), Brandi L. Povitz (Author), Samantha Medwid (Author), Wendy A. Teft (Author), Robin M. Legan (Author), John Lenehan (Author), Stephanie Nevison (Author), Veera Panuganty (Author), Denise Keller (Author), Jaymie Mailloux (Author), Victoria Siebring (Author), Sisira Sarma (Author), Yun‐hee Choi (Author), Stephen Welch (Author), Eric Winquist (Author), Ute I. Schwarz (Author), Richard B. Kim (Author)
• Format: Book
• Published: Wiley, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Consensus guidelines exist for genotype‐guided fluoropyrimidine dosing based on variation in the gene dihydropyrimidine dehydrogenase (DPYD). However, these guidelines have not been widely implemented in North America and most studies of pretreatment DPYD screening have been conducted in Eu...